(6R*,16R*)-9,14-dihydro-6-methyl-6,16-methano-6H,16H-[2,4]benzothiazepino[3,4-d][1,3,5]benzoxadi-azocine hydrobromide dimethylformamide hemisolvate

Citation
V. Kettmann et J. Svetlik, (6R*,16R*)-9,14-dihydro-6-methyl-6,16-methano-6H,16H-[2,4]benzothiazepino[3,4-d][1,3,5]benzoxadi-azocine hydrobromide dimethylformamide hemisolvate, ACT CRYST C, 56, 2000, pp. 1115-1116
Citations number
13
Categorie Soggetti
Physical Chemistry/Chemical Physics
Journal title
ACTA CRYSTALLOGRAPHICA SECTION C-CRYSTAL STRUCTURE COMMUNICATIONS
ISSN journal
01082701 → ACNP
Volume
56
Year of publication
2000
Part
9
Pages
1115 - 1116
Database
ISI
SICI code
0108-2701(200009)56:<1115:(>2.0.ZU;2-A
Abstract
The title compound, C19H19N2OS+. Br-. 0.5C(3)H(7)NO, is an oxygen-bridged p henylpyrimidine derivative in which the heterocyclic ring is protonated, th e positive charge being dispersed over both of the N atoms. Both molecules in the asymmetric unit exist in an identical conformation, which consists o f a central planar portion with the two terminal phenyl rings protruding fr om the same side of the plane. One of the independent molecules forms a str ong hydrogen bond with the bromide anion, while the other is hydrogen bonde d to the dimethylformamide solvent molecule.